Skip to main
We’re doing some system maintenance
  1. /
  2. Stocks
  3. /
  4. Athira Pharma

Buy Athira Pharma (ATHA) Stock

See ATHA stock price and Buy/Sell Athira Pharma with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Athira Pharma (ATHA)

About Athira Pharma (ATHA)

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
Market Cap
1 Year High
1 Year Low
Price to Earnings Ratio
Dividend Rate
Dividend Yield


People who own or watch ATHA stock

Athira Pharma Price Targets

What analysts think ATHA stock price will be.
466.7% Upside

Athira Pharma Stock Rating

What analysts recommend for ATHA stock, on a scale from 1(buy) to 5(sell).
Buy2.3 / 5

Athira Pharma Stock Earnings

The value each ATHA share was expected to gain vs. the value that each ATHA share actually gained.

Athira Pharma Stock News

Frequently Asked Questions (FAQ)

As of Oct 01, 2022, the market cap for ATHA stock is $112.32M

The 52-week high for ATHA stock is $16.65. The current ATHA stock price $2.97 is 82.16% below its 52-week high

The 52-week low for ATHA stock is $2.53. The current ATHA stock price $2.97 has increased 14.81% from its 52-week low

No, the ATHA stock does not pay dividends to its shareholders

The target price for ATHA stock is $16.83 based on the average of what a group of analyst think ATHA stock could be worth at a future date. This is not a prediction by

Buy Athira Pharma (ATHA) Stock

See ATHA stock price and Buy/Sell Athira Pharma with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing


People who own or watch ATHA stock
  • pjcrosson avatar
  • markt3309 avatar
  • jaydee44 avatar
  • sammied avatar
  • sovereigntrader avatar
Contact Us
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Brokerage services for US-listed, registered securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Our clearing firm, Apex Clearing Corporation, has purchased an additional insurance policy. The coverage limits provide protection for securities and cash up to an aggregate of $150 million, subject to maximum limits of $37.5 million for any one customer’s securities and $900,000 for any one customer’s cash. Similar to SIPC protection, this additional insurance does not protect against a loss in the market value of securities.

Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are over-the-counter equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”). Dalmore and Open to the Public Investing are not affiliated entities. This content is not investment advice. These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. An affiliate of Public may be “testing the waters” and considering making an offering of securities under Tier 2 of Regulation A. No money or other consideration is being solicited and, if sent in response, will not be accepted. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification by the SEC or as stated in the offering materials relating to an investment opportunity, as applicable. An indication of interest to purchase securities involves no obligation or commitment of any kind.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures, Apex Crypto.

Dalmore and Apex Crypto, LLC are not affiliated with any of the Public Holdings subsidiaries.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S.-listed, registered securities electronically. Keep in mind that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.